Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first- line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

被引：5
|
作者：
Tahara, Makoto
Kiyota, Naomi
Yokota, Tomoya
Hasegawa, Yasuhisa
Muro, Kei
Takahashi, Shunji
Onoe, Takuma
Homma, Akihiro
Taguchi, Jun
Suzuki, Masami
Minato, Koichi
Yane, Katsunari
Ueda, Shinya
Hara, Hiroki
Saijo, Ken
Yamanaka, Takeharu
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Kobe Univ Hosp, Div Med Oncol & Hematol, Dept Med, Kobe, Hyogo, Japan
[3] Grad Sch Med, Kobe, Hyogo, Japan
[4] Shizuoka Canc Ctr, Shizuoka, Japan
[5] Aichi Caner Ctr, Nagoya, Aichi, Japan
[6] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[7] Ctr Canc Chemotherapy, Tokyo, Japan
[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[9] Hyogo Canc Ctr, Dept Med Oncol, Akashi, Hyogo, Japan
[10] Hokkaido Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sapporo, Hokkaido, Japan
[11] Hokkaido Univ Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[12] Gunma Prefectural Canc Ctr, Ota, Japan
[13] Gunma Prefectural Canc Ctr, Div Resp Med, Ota Shi, Japan
[14] Nara Hosp Kinki Univ, Fac Med, Ikoma, Japan
[15] Kinki Univ, Dept Med Oncol, Fac Med, Osaka, Japan
[16] Saitama Canc Ctr Hosp, Dept Gastroenterol, Saitama, Japan
[17] Tohoku Univ, Sendai, Miyagi, Japan
[18] Yokohama City Univ, Dept Biostat, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6026
引用
收藏
页数：3
相关论文
共 50 条
  • [31] High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
    Chauffert, Bruno
    Zhou, Yuedan
    Medjkoune, Liza
    Ouikene, Abdenour
    Galez, Agnes
    Belkhir, Farid
    Saint-Germain, Pierre
    Youssef, Ali
    Chehimi, Mohamad
    CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 13 - 20
  • [32] A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
    Paul L. Swiecicki
    Greg Durm
    Emily Bellile
    Apurva Bhangale
    J. Chad Brenner
    Francis P. Worden
    Investigational New Drugs, 2020, 38 : 1550 - 1558
  • [33] A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
    Swiecicki, P. L.
    Durm, G.
    Bellile, E.
    Brummel, C.
    Pang, M.
    Bhangale, A.
    Brenner, J. C.
    Worden, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1178 - 1179
  • [34] A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
    Swiecicki, Paul L.
    Durm, Greg
    Bellile, Emily
    Bhangale, Apurva
    Brenner, J. Chad
    Worden, Francis P.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1550 - 1558
  • [35] Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
    Argiris, A.
    Kotsakis, A. P.
    Hoang, T.
    Worden, F. P.
    Savvides, P.
    Gibson, M. K.
    Gyanchandani, R.
    Blumenschein, G. R., Jr.
    Chen, H. X.
    Grandis, J. R.
    Harari, P. M.
    Kies, M. S.
    Kim, S.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 220 - 225
  • [36] Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
    Carinato, H.
    Burgy, M.
    Fischbach, C.
    Kalish-Weindling, M.
    Pabst, L.
    Frasie, V.
    Thiery, A.
    Coliat, P.
    Demarchi, M. F.
    Petit, T.
    Borel, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S668 - S668
  • [37] Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck
    Bernier, Jacques
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (12): : 705 - 713
  • [38] Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck
    Jacques Bernier
    Nature Clinical Practice Oncology, 2008, 5 : 705 - 713
  • [39] Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients
    Carinato, Helene
    Burgy, Mickael
    Ferry, Regine
    Fischbach, Cathie
    Kalish, Michal
    Guihard, Sebastien
    Brahimi, Youssef
    Flesch, Henri
    Bronner, Guy
    Schultz, Philippe
    Frasie, Veronique
    Thiery, Alicia
    Demarchi, Martin
    Petit, Thierry
    Jung, Alain C.
    Wagner, Pierre
    Coliat, Pierre
    Borel, Christian
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [40] Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
    Bernier, Jacques
    ONCOLOGY REVIEWS, 2009, 3 (04) : 247 - 256
12345